The reimbursement prices of big-selling immuno-oncology products Opdivo (nivolumab) and Keytruda (pembrolizumab) are to be cut again at the time of the general drug price revision in Japan on April 1, adding to earlier one-off reductions for the two PD-1 inhibitors.
The reimbursement level awarded by Japan’s national health insurance will be reduced by around 24% and 11% respectively for the two drugs due to new sales considerations and cost-effectiveness calculations applied as part of revised methodology under the regular biennial price cut, which this time will also see the application of a foreign price comparison (involving selected major
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?